StreetAlpha.app
Home › Stocks › IMUX

Immunic, Inc. (IMUX)

Healthcare
$7.33
▲ +1.38%
LAST CLOSE · NOV 17

Immunic is a biotechnology company developing oral drugs for multiple sclerosis and gastrointestinal diseases. It last closed at $7.33 on Nov 17, up 1.38% on the day.

AI Auto Pilots
Is IMUX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$128.3M
Free cash flow
−$96.3M
Valuation
Market cap
$116.4M
15.9M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$132.0M
At Sep 30
Shareholder equity
$104.5M
Shares outstanding
15.9M
At Nov 6
Employees85 (Aug 1, 2024)
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$92.9M−$92.9MFY2021FY2022: −$120.4M−$120.4MFY2022FY2023: −$93.6M−$93.6MFY2023FY2024: −$100.5M−$100.5MFY2024FY2025: −$97.2M−$97.2MFY2025

From IMUX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Last report
Nov 13
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated IMUX in the past 90 days, not enough for a consensus
Average 12-month target
$45.00
▲ 513.9% upside

Based on 1 analyst who set a price target on IMUX in the past 90 days. The average target is $45.00, with a high of $45.00 and a low of $45.00, compared with the last close of $7.33.

Low $45.00Avg $45.00High $45.00
Blue marker: last close $7.33
Highest target$45.00
Average target$45.00
Lowest target$45.00
Latest rating changes
WedbushReiterated
Sep 10Buy$45
WedbushInitiated
Aug 17Buy$45
B. Riley SecuritiesMaintained
May 22Buy$27
StifelInitiated
Apr 17Buy$2.50
DateFirmActionRatingPrice target
Sep 10WedbushReiteratedBuy$45
Aug 17WedbushInitiatedBuy$45
May 22B. Riley SecuritiesMaintainedBuy$27
Apr 17StifelInitiatedBuy$2.50
Loading…

Technical Analysis

IMUX · as of the Nov 17 close · updated after every close
Downtrend

The stock is 4% below its 20 day and 16% below its 50 day average. It is 58% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 42). The nearest support is the Pivot at $7.30, and the nearest resistance the Pivot R1 at $7.52.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 7.9%/day
Key levels
$17.4352 week high+137.8%
$11.70100 day average+59.6%
$11.57200 day average+57.8%
$8.4750 day average+15.6%
$8.22Swing high (Oct 29)+12.1%
$7.6120 day average+3.8%
$7.52Pivot R1+2.6%
$7.33Last close
$7.30Pivot−0.4%
$7.16Swing low (Nov 2)−2.3%
$7.12Pivot S1−2.9%
$5.0652 week low−31.0%
Indicators
RSI (14)41.89Middle of its rangeNeutral
MACD-0.27Above its signal lineBullish
Stochastic17.8Near the bottom of its rangeOversold
ADX (14)16.9No clear trend
Williams %R-81.8Oversold below −80, overbought above −20Oversold
CCI (20)-107.1Oversold below −100, overbought above 100Oversold
Rate of change−3.5%Change over 10 sessionsBearish
ATR (14)$0.58Typical daily range, 7.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IMUX

What happened before

See how IMUX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow IMUX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IMUX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in IMUX in the last 90 days.

Loading…

See today’s whale options flow across the market →

IMUX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲47 buying vs 18 selling
  • ▲Held by funds +14.0 pts
  • ▲Funds holding +21
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7756+37.5%
In funds' top 1020–
Held by funds68.7%54.7%+14.0 pts
New / increased28 / 1954 / 1−14.5%
Reduced / sold out11 / 71 / 76−76.6%
Put/call ratio0.090.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IMUX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMUX is in one of them and how their past IMUX trades turned out.

IMUX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IMUX in an article yet. Here's the latest on the wider market.

About Immunic

Immunic is a biotechnology company that develops oral drugs for neurologic and gastrointestinal diseases. Its lead candidate, vidofludimus calcium, is in Phase 3 testing for relapsing multiple sclerosis, and its IMU-856 candidate is being developed for conditions such as celiac disease and inflammatory bowel disease. The company has no products approved for sale yet and has not generated revenue from product sales. It is headquartered in New York, with its main research operations in Germany.

Headquarters
New York